Lockwood K, Moesgaard S, Yamamoto T, Folkers K
Pharma Nord, Vejle, Denmark.
Biochem Biophys Res Commun. 1995 Jul 6;212(1):172-7. doi: 10.1006/bbrc.1995.1952.
Over 35 years, data and knowledge have internationally evolved from biochemical, biomedical and clinical research on vitamin Q10 (coenzyme Q10; CoQ10) and cancer, which led in 1993 to overt complete regression of the tumors in two cases of breast cancer. Continuing this research, three additional breast cancer patients also underwent a conventional protocol of therapy which included a daily oral dosage of 390 mg of vitamin Q10 (Bio-Quinone of Pharma Nord) during the complete trials over 3-5 years. The numerous metastases in the liver of a 44-year-old patient "disappeared," and no signs of metastases were found elsewhere. A 49-year-old patient, on a dosage of 390 mg of vitamin Q10, revealed no signs of tumor in the pleural cavity after six months, and her condition was excellent. A 75-year-old patient with carcinoma in one breast, after lumpectomy and 390 mg of CoQ10, showed no cancer in the tumor bed or metastases. Control blood levels of CoQ10 of 0.83-0.97 and of 0.62 micrograms/ml increased to 3.34-3.64 and to 3.77 micrograms/ml, respectively, on therapy with CoQ10 for patients A-MRH and EEL.
在过去35年里，关于维生素Q10（辅酶Q10；CoQ10）与癌症的生化、生物医学及临床研究数据和知识在国际上不断发展，这在1993年使得两例乳腺癌患者的肿瘤明显完全消退。继续这项研究，另外三名乳腺癌患者也接受了常规治疗方案，在为期3至5年的完整试验期间，每天口服390毫克维生素Q10（法尔诺德的生物醌）。一名44岁患者肝脏中的大量转移瘤“消失”，其他部位未发现转移迹象。一名49岁患者，服用390毫克维生素Q10六个月后，胸腔内未发现肿瘤迹象，病情良好。一名75岁单乳癌患者，在进行肿块切除术后服用390毫克CoQ10，肿瘤床及转移部位均未发现癌症。患者A - MRH和EEL在接受CoQ10治疗时，血液中CoQ10的对照水平分别从0.83 - 0.97微克/毫升和0.62微克/毫升升至3.34 - 3.64微克/毫升和3.77微克/毫升。
